[Chemoendocrine therapy of gastric "scirrhous" carcinoma].
An oral chemoendocrine treatment using Tamoxifen and FT-207 for female patients with gastric scirrhous carcinoma was developed at the National Cancer Center. The dose was oral Tamoxifen 20 mg/day b.i.d. combined with FT-207, 600 mg/day t.i.d. Since the results of the pilot trial were promising, a double-blind clinical study was performed in the National Cancer Center Hospital. In patients with non-curative surgery, the group of Tamoxifen and FT-207 had longer survival than those who received only FT-207 (p = 0.084) by the Generalized Wilcoxon's analysis. To confirm these results, a controlled clinical study is being undertaken with patients of both sexes, of scirrhous and non-scirrhous types, and in all after non-curative surgery.
Ohkura
H
H
Division of Internal Medicine, National Cancer Center Hospital.
Kitaoka
H
H
D002293:Adenocarcinoma, Scirrhous / Q000188:drug therapy* / Q000401:mortality; D000284:Administration, Oral; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality; D013629:Tamoxifen / Q000008:administration & dosage*; D005641:Tegafur / Q000008:administration & dosage
D008937:Mitomycins; D013629:Tamoxifen; D005641:Tegafur; D016685:Mitomycin